Logo-Cellfbio-Tagline-400x400 (1).jpg
Cellf BIO Begins Phase 1 Clinical Trial of BioSphincter™ Implant for Fecal Incontinence
January 05, 2023 09:18 ET | CELLF-BIO, LLC
RICHMOND, Va., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Cellf BIO, a biotechnology company that manufactures bioengineered sphincters using autologous progenitor cells, announced today that it has begun its...
Logo.jpg
Updated Invectys and CTMC announce FDA clearance of IND application for anti-HLA-G CAR-T cell therapy
December 20, 2022 08:50 ET | Invectys, Inc.
FDA granted IND clearance for IVS-3001, Invectys’s lead engineered anti-HLA-G CAR-T cell therapy, for the treatment of patients with solid tumors HOUSTON, Texas, Dec. 20, 2022 (GLOBE NEWSWIRE) --...
Logo.jpg
Invectys and CTMC announce FDA clearance of IND application for anti-HLA-G CAR-T cell therapy
December 19, 2022 10:24 ET | Invectys, Inc.
FDA granted IND clearance for IVS-3001, Invectys’s lead engineered anti-HLA-G CAR-T cell therapy, for the treatment of patients with solid tumorsHOUSTON, Texas, Dec. 19, 2022 (GLOBE NEWSWIRE) --...
Nurix.png
Nurix Therapeutics Announces Clearance of Investigational New Drug Application for NX-5948 Supporting Plans to Expand Enrollment to U.S. Clinical Sites
December 15, 2022 16:01 ET | Nurix Therapeutics, Inc.
NX-5948 is being evaluated in patients with relapsed and refractory B-cell malignancies Phase 1 clinical trial now enrolling patients in the United Kingdom with plans to expand to clinical sites in...
Arch Biopartners Submits Investigational New Drug Application to the FDA for Metablok (LSALT peptide)
June 08, 2020 07:00 ET | Arch Biopartners
TORONTO, June 08, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
arch.png
Arch Biopartners Submits Application to Health Canada to Conduct COVID19 Phase II Human Trial for Metablok to Prevent Lung and Kidney Inflammation
April 23, 2020 16:54 ET | Arch Biopartners
TORONTO, April 23, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company developing new drug candidates for treating...
arch.png
Arch Scientists Publish Data on the Mechanism of Action and Efficacy of Lead Drug Candidate Metablok in the Prevention of Inflammation and Organ Damage
August 22, 2019 12:24 ET | Arch Biopartners
TORONTO, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that a scientific team led by Dr. Donna Senger, Dr....
logo.png
Arch Biopartners Closes $1.25M Non-Brokered Private Placement Financing
March 09, 2018 08:00 ET | Arch Biopartners
TORONTO, March 09, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (Arch or the Company) (TSX Venture:ARCH) and (OTCBB:ACHFF), announced today it has closed the non-brokered private placement the...
logo.png
Arch Biopartners Announces Start of GMP Manufacturing for Metablok at CSBio
February 27, 2018 07:30 ET | Arch Biopartners
TORONTO, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners, Inc., (Arch or the Company) (TSX-V:ARCH) (OTCBB:ACHFF) a portfolio-based biotechnology company, today announced CSBio of Menlo Park,...
C3 Jian Obtains FDA
C3 Jian Obtains FDA Acceptance of Investigational New Drug Application
May 24, 2012 12:06 ET | C3 Jian, Inc.
LOS ANGELES, May 24, 2012 (GLOBE NEWSWIRE) -- C3 Jian, Inc., a private company focused on providing improved oral healthcare, announced today that its Investigational New Drug Application (IND) for...